Sign In
Buy FATE
$2.22
-0.350 (-13.62%)
At Close: Jun 03, 2026
Did You See What Cathie Wood Bought on Wednesday?
11:40am, Thursday, 22'nd Jul 2021
ARK Invest added to its stakes in DraftKings, Fate Therapeutics, and Zoom Video, all of which are trading well below their recent peaks.
SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
04:01pm, Thursday, 15'th Jul 2021
SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for
IDNA: Genetics Now Have A Lot Of Influence On Healthcare
03:12am, Saturday, 10'th Jul 2021
IDNA: Genetics Now Have A Lot Of Influence On Healthcare
Cathie Wood's ARK Invest Buys Over 530,000 Shares of Fate Therapeutics
09:05am, Thursday, 08'th Jul 2021
One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Wednesday.
Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer
08:00am, Tuesday, 15'th Jun 2021
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for
Fate Therapeutics: Strong Early Stage Data
07:31am, Sunday, 13'th Jun 2021
Fate Therapeutics is a pioneer in induced pluripotent stem cell research. They have been a research company mainly for nearly 15 years.
The Rally Likely To Continue For Fate Therapeutics After Positive Clinical Trials Data
08:30am, Thursday, 10'th Jun 2021
The stock price of Fate Therapeutics, a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a 9% rise over the last five trading
Fate Therapeutics Stock is Trading Higher on Positive B-Cell Lymphoma Data at ASCO21
03:06pm, Friday, 04'th Jun 2021
Fate Therapeutics Inc (NASDAQ: FATE) has revealed some new data from an ongoing Phase 1 trial evaluating FT516 for patients with relapsed / refractory B-cell lymphoma. Data were presented at the 20
Why Is Fate Therapeutics (FATE) Down 12.2% Since Last Earnings Report?
12:47pm, Friday, 04'th Jun 2021
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?
8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response
The Best Biotech Stocks to Buy With $500
06:01am, Monday, 31'st May 2021
A modest amount goes a long way when you invest in biotech stocks.
Fate Therapeutics to Present at Upcoming Investor Conferences
04:01pm, Tuesday, 25'th May 2021
SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for c
Fate Therapeutics' iPSC-Derived Cell Therapies Induce Leukemic Blast Clearance, Show Durable Remissions In AML Patients
08:17am, Friday, 14'th May 2021
Fate Therapeutics Inc (NASDAQ: FATE) has announced interim data from Phase 1 data from the Company's off-the-shelf, iPSC-derived natural killer (NK) cell programs in relapsed / refractory acute my
FATE Reports Wider-Than-Expected Q1 Loss, Beats on Revenues
02:16pm, Thursday, 06'th May 2021
FATE reports a wider Q1 loss on increased R&D expenses.
